EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer

Sora Kang iD, Sung-Bae Kim iD

Therapeutic Advances in Medical Oncology · 2025-01 · 17

DOI: 10.1177/17588359251324889 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 24.03.2025. Verfasst von Sora Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) offer a promising therapeutic approach for various cancers, enhancing the therapeutic window while mitigating systemic adverse effects on healthy tissues. ADCs have achieved remarkable clinical success, particularly in treating breast cancer, becoming a standard therapy across all subtypes, including hormone receptor-positive, human epidermal growth factor receptor 2-positive, and triple-negative breast cancer. Although designed to selectively target antigens via monoclonal antibodies, ADCs can exhibit toxicity in normal tissues, often due to off-target effects of their cytotoxic payloads. Understanding and managing these toxicities according to established guidelines are crucial for enhancing ADC clinical efficacy, minimizing adverse events, and ultimately improving patient outcomes. This review comprehensively examines the toxicities of ADCs employed in breast cancer treatment and explores their management strategies. Furthermore, we investigate novel ADCs beyond trastuzumab deruxtecan and sacituzumab govitecan, evaluating their potential efficacy and corresponding safety profiles.

Schlagwörter

Stichwörter der Autor:innen

adverse eventsantibody–drug conjugatesbreast cancertrastuzumab deruxtecan

Autor:innen und Institutionen

  • Division of Hemato-Oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.

ORCID-Profile: Sora Kang, Sung-Bae Kim

Zitieren

APA

Kang, S., & Kim, S. B. (2025). Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251324889

Vancouver

Kang S, Kim SB. Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251324889

BibTeX
@article{Kang2025,
  author = {Kang, Sora and Kim, Sung-Bae},
  title = {Toxicities and management strategies of emerging antibody–drug conjugates in breast cancer},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359251324889}
}
Kostenlos starten →